Disposition kinetics of kanamycin in mules

Similar documents
Pharmacokinetics of the Bovine Formulation of Enrofloxacin (Baytril 100) in Horses

VETERINARSKI ARHIV 80 (2), , administration. Vet. arhiv 80, , ABSTRACT. *Corresponding author:

SZENT ISTVÁN UNIVERSITY. Doctoral School of Veterinary Science

Pierre-Louis Toutain, Ecole Nationale Vétérinaire National veterinary School of Toulouse, France Wuhan 12/10/2015

Introduction to Pharmacokinetics and Pharmacodynamics

Intramuscular Pharmacokinetics and Milk Levels of Ceftriaxone in Endometritic Cows

PHARMACOKINETICS OF FLUNIXIN IN BUFFALO CALVES AFTER SINGLE INTRAMUSCULAR ADMINISTRATION. M.M. Gatne*, M.H. Yadav and T.R. Mahale

PHARMACOKINETICS OF LINCOMYCIN FOLLOWING SINGLE INTRAMUSCULAR ADMINISTRATION IN GOATS MEEMANSHA SHARMA, BHASKAR VEMU & VINOD KUMAR DUMKA

GENTAMICIN DISPOSITION IN CEREBROSPINAL FLUID (CSF) AND AQUEOUS HUMOUR IN HEALTHY DOGS

DISPOSITION STUDY OF MELOXICAM ALONE AND ALONG WITH ENROFLOXACIN IN MALE BUFFALO CALVES AFTER INTRAVENOUS ROUTE

European Public MRL assessment report (EPMAR)

SUMMARY OF PRODUCT CHARACTERISTICS

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

IJCBS, 10(2016): International Journal of Chemical and Biochemical Sciences (ISSN )

EXCEDE Sterile Suspension

Kinetic Studies of Enrofloxacin after Intravenous Administration in Yak

Disposition kinetics of long acting moxifloxacin following intravenous administration in Sheep

Research Article Disposition Kinetic of Moxifloxacin following Intravenous, Intramuscular, and Subcutaneous Administration in Goats

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

Jerome J Schentag, Pharm D

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

Baytril 100 (enrofloxacin) Injectable is FDA-approved for BRD control (metaphylaxis) in high-risk cattle.

International Journal of Advances in Pharmacy and Biotechnology Vol.3, Issue-2, 2017, 1-7 Research Article Open Access.

Original Research Article

Pharmacokinetic & Pharmadynamic of Once Daily Aminoglycosides (ODA) and their Monitoring. Janis Chan Pharmacist, UCH 2008

BOX 1. NAME OF THE VETERINARY MEDICINAL PRODUCT. Hymatil 300 mg/ml solution for injection for cattle and sheep Tilmicosin

Pharmacological Evaluation of Amikacin in Neonates

VETERINARSKI ARHIV 84 (3), , 2014

single intravenous and oral doses and after 14 repeated oral

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) REVISED GUIDELINE ON THE SPC FOR ANTIMICROBIAL PRODUCTS

The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens

PHARMACOKINETIC VARIATIONS OF OFLOXACIN IN NORMAL AND FEBRILE RABBITS

Application of Pharmacokinetics/ Pharmacodynamics (PK/PD) in Designing Effective Antibiotic Treatment Regimens

BIOEQUIVALENCE STUDY ON TWO BRANDS OF 10% ENROFLOXACIN ORAL FORMULATIONS IN CHICKENS. * Corresponding author:

Concentration of Enrofloxacin Residue from Tilapia (Oreochromis niloticus) Muscular That Infected by Aeromonas salmonicida

Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and

Irish Greyhound Board. Scientific Advisory Committee on Doping and Medication Control. Opinion on Carprofen

European public MRL assessment report (EPMAR)

Pharmacokinetics of amikacin in febrile neutropenic pediatric patients with acute lymphoblastic leukaemia

Pharmacokinetics and urinary excretion of sulfadiazine in buffalo calves

) in buffaloes was 1.09 ± 0.06 l/kg, cows 1.24 ± 0.16 l/kg, sheep 2.89 ± 0.30 l/kg and goats 3.76 ± 0.92 l/kg. Total body clearance (Cl B

Comparative efficacy of various indigenous and allopathic drugs against fasciolosis in buffaloes

PHARMA SCIENCE MONITOR AN INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES PHARMACOKINETIC INTERACTION OF MOXIFLOXACIN AND

Influence of ofloxacin on the disposition kinetics of meloxicam following single intravenous administration in goats

SUMMARY OF PRODUCT CHARACTERISTICS

ABSTRACT. The effect of exogenous oxytocin injected on different days of estrus cycle and pregnancy on uterine PGF 2a

Serum chloramphenicol levels and the intramuscular bioavailability of several parenteral formulations of chloramphenicol in ruminants

Recommended for Implementation at Step 7 of the VICH Process on 15 December 2004 by the VICH Steering Committee

SUMMARY OF PRODUCT CHARACTERISTICS. NUFLOR 300 mg/ml solution for injection for cattle and sheep

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

Patients. Excludes paediatrics, neonates.

Pharmacokinetics and penetration of danofloxacin from the blood into the milk of cows

Antimicrobial Pharmacodynamics

B. PACKAGE LEAFLET 1

J. vet. Pharmacol. Therap. doi: /jvp SHORT COMMUNICATION H. K. KNYCH*, S. D. STANLEY*, R. M. ARTHUR & D. S. MCKEMIE*

Effect of Ketoprofen Co-Administration and Febrile State on Pharmacokinetics of Levofloxacin in Goats Following Intravenous Administration

THE STABILITY OF E1VROFLOXA CIN University Undergraduate Research Fellow. A Senior Thesis. Texas ASM University.

SUMMARY OF PRODUCT CHARACTERISTICS 1.B.1 SUMMARY OF PRODUCT CHARACTERISTICS

USA Product Label CLINTABS TABLETS. Virbac. brand of clindamycin hydrochloride tablets. ANADA # , Approved by FDA DESCRIPTION

ZOETIS INC. 333 PORTAGE STREET, KALAMAZOO, MI, Telephone: Customer Service: Website: EXCEDE FOR SWINE

SUMMARY OF PRODUCT CHARACTERISTICS

Effect of Febrile Condition and Ketoprofen Co-administration on Pharmacokinetics of Moxifloxacin Following Intravenous Administration in Sheep

4.5. Special precautions for use Special precautions to be taken by person administering the veterinary medicinal product to animals

Only for Intravenous Use in Beef and Dairy Cattle. Not for Use in Dry Dairy Cows and Veal Calves. For Intravenous or Intramuscular Use in Horses.

1 TRADE NAME OF THE MEDICINAL PRODUCT. Gentamicin Paediatric 20mg/2ml Solution for Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

A Field Study on Efficacy of Albendazole (Albezol ) Against Gastro-intestinal Nematodes in Ruminants

Summary of Product Characteristics

SUMMARY OF PRODUCT CHARACTERISTICS

Percent Time Above MIC ( T MIC)

Antibiotics in vitro : Which properties do we need to consider for optimizing our therapeutic choice?

POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS OF OFLOXACIN IN SOUTH AFRICAN PATIENTS WITH DRUG- RESISTANT TUBERCULOSIS

Proceedings of the 13th International Congress of the World Equine Veterinary Association WEVA

European public MRL assessment report (EPMAR)

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

COMPARISON OF AMIKACIN PHARMACOKINETICS IN A KILLER WHALE (ORCINUS ORCA) AND A BELUGA WHALE (DELPHINAPTERUS LEUCAS)

Metacam 1.5 mg/ml oral suspension for dogs

Sepsis is the leading cause of morbidity and mortality in

SELECT NEWS. Florfenicol Monograph: Injectable Therapy for Cattle

Session 1: An introduction to the new requirements under the Food and Drug Regulations affecting industry and health care practitioners who compound

PHARMACOKINETICS OF AMIKACIN AFTER A SINGLE INTRAVENOUS DOSE AND RESULTANT CONCENTRATIONS IN BODY FLUIDS OF THE HORSE

Pharmacokinetics of amoxycillin and clavulanic acid in

Research Article Comparative Pharmacokinetics of Levofloxacin in Healthy and Renal Damaged Muscovy Ducks following Intravenous and Oral Administration

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian.

DETERMINANTS OF TARGET NON- ATTAINMENT IN CRITICALLY ILL PATIENTS RECEIVING β-lactams

Aspects of the Chronic Toxicity of Gentamicin Sulfate in Cats

Sales survey of Veterinary Medicinal Products containing Antimicrobials in France

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/33

ANNEX III LABELLING AND PACKAGE LEAFLET

Oral pharmacokinetics of fenbendazole in llamas, South American Camelids

ANTICOCCIDIALS USED FOR THE THERAPY OF COCCIDIOSIS IN CHICKENS, TURKEYS AND GEESE

FACULTAT DE VETERINÀRIA DE BARCELONA

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/12

Curriculum Vitae. Dr. Jan Mohammad Shah

Sales survey of Veterinary Medicinal Products containing Antimicrobials in France Volumes and estimated exposure of animals to antimicrobials

MARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS

Transcription:

VETERINARSKI ARHIV 73 (4), 221-226, 2003 Disposition kinetics of kanamycin in mules Faqir Muhammad, Faqir Hussain, Muhammad Nawaz, and Ijaz Javed* Department of Physiology and Pharmacology, Faculty of Veterinary Science, University of Agriculture, Faisalabad, Pakistan MUHAMMAD, F., F. HUSSAIN, M. NAWAZ, I. JAVED: Disposition kinetics of kanamycin in mules. Vet. arhiv 73, 221-226, 2003. ABSTRACT The disposition kinetics of kanamycin was investigated following an injection of a single intravenous dose 5 mg/kg body mass in healthy adult female mules. Blood samples collected at various time intervals post-medication were analyzed for kanamycin by microbiological assay. The plasma drug concentration versus time data was best fitted by a biexponential expression. Macro-kinetic parameters were computed for a two-compartment open model. Values for distribution half-life (t 1/2á) ) and elimination half-life (t 1/2 ß ) were 0.18 ± 0.26 and 4.39 ± 0.68 h, respectively. The apparent volume of distribution (V d ) was 0.64 ± 0.17 L/kg. Total body clearance (Cl B ) of the drug was 1.66 ± 0.22 ml/ min.kg. Existing dosage of 5 mg/kg body mass at 24 h intervals does not maintain the desired minimum inhibitory concentration (MIC) at the end of proposed dosing intervals. Calculated optimal dosage regimen for kanamycin in mules was 8.73 and 7.45 mg/kg body mass for priming and maintenance, respectively, for a dosage interval of 12 h to maintain the concentration of 2 µg/ml in blood. Key words: kanamycin, disposition kinetics, mule Introduction Most developing countries are importing either raw active substance or finished drugs for human and veterinary use. Dosage regimens for these drugs are often based on studies carried out in foreign environments and species of animals. Generally speaking, in drug-importing countries * Contact address: Prof. Dr. Ijaz Javed Hassan, Department of Physiology and Pharmacology, Faculty of Veterinary Science, University of Agriculture, Faisalabad 38040, Pakistan, Phone: +92 41 920 0161 71 Ext 3104; Fax: +92 41 647 846; E-mail: mzargham@fsd.paknet.com.pk ISSN 0372-5480 Printed in Croatia 221

environmental conditions and the genetic make-up of indigenous animals which affect the biodisposition and fate of drugs are different from their foreign counterparts. These differences are described by the original term geonetics (NAWAZ and SHAH, 1985; NAWAZ et al., 1988; NAWAZ, 1994). As a consequence of geonetical variations the optimal therapeutic usage of imported drugs should be determined in both the target species and their environments. Kanamycin is an extensively used antibiotic for susceptible infections in animals. Mules are important draught animals. Therefore, the disposition kinetics of kanamycin was investigated in order to propose an optimal intravenous dosage regimen of the drug. Materials and methods The disposition kinetics of kanamycin was investigated during the month of April in 8 healthy adult female mules maintained on a farm at Sargodha, Pakistan. Average body mass of the mules was 386 kg (range 375 410 kg). Animals were kept under similar management conditions. Prior to drug administration a control blood sample was drawn from the jugular vein and each animal was given kanamycin in a single intravenous dose of 5 mg/kg. b.m. (Kanachron 10%, Batch No. VD 124, Star Laboratories, Lahore, Pakistan Ltd.). Blood samples were collected in heparinized centrifuge tubes at 5, 10, 15, 30, 60 minutes and then at 1.5, 2, 2.5, 3, 4, 6, 8, and 10 hours after drug administration. Blood samples were centrifuged at 500 g for 10 minutes and plasma was separated and stored at freezing point until analysis. Concentration of kanamycin in plasma was determined by microbiological assay (ARRET et al., 1971) using Staphylococcus aureus as a test organism. Standard curves of kanamycin 1, 2, 4, 6, 8 mg/ml in plasma and distilled water when plotted against the zone of inhibition revealed regression equation y = 0.5395 e0.2482 x and a value of R 2 = 0.9754. The plasma concentration versus time data was used to calculate several pharmacokinetics parameters using a PC program, MWPHARM version 3.02, a MEDIWARE product, Holland. This program calculates area under curve (AUC) from time t to a by polyexponential and trapezoidal rule 222 Vet. arhiv 73 (4), 221-226, 2003

methods and the regression coefficient of best-fit to depict the compartmental analysis for pharmacokinetic parameters (BAGGOT, 1977). The pharmacokinetic parameters were used to calculate the optimal dosage regimen for kanamycin in mules. Results and discussion Plasma concentration of kanamycin versus time data plotted on a semilog scale depicted a biexponential decline (Fig. 1). This is similar to that noted in other species, such as the horse, dog and sheep (BAGGOT, 1978), sheep, goat, rabbit, chicken and pigeon (LASHEV et al., 1992) and cattle (GHAFFAR et al., 1996). Average ± SD values of the pharmacokinetic parameters calculated for a two compartment model are shown in Table 1. Concentration µg/ml Time (hours) Fig. 1. Average plasma concentration (µg/ml) of kanamycin in mules against time after single (i/v) injection of 5 mg/kg body mass The elimination half-life of kanamycin in mules of 4.39 hours was longer than the 1.4 hours in horse, 1.65 hrs in sheep, 0.74 hour in dog (BAGGOT, 1977); 1.8 hours in the horse (BAGGOT et al., 1981); 2.36 hours in buffaloes (FUHUA et al., 1989); 1.81 hours in sheep, and 1.95 hour in goats Vet. arhiv 73 (4), 221-226, 2003 223

(LASHEV et al., 1992). The apparent volume of distribution (Vd) calculated by the area method was 0.64 L/kg, which is higher than 0.17 L/kg in horse, 0.23 L/kg in dog and 0.22 L/kg in sheep (BAGGOT et al., 1977), and 0.23 L/ kg in horse (BAGGOT et al., 1985). The difference was due to a lower value of B, the extrapolated zero time plasma drug concentration of the elimination phase in mules. Total body clearance (Cl B ) of kanamycin in mules was 1.66 ml/min.kg, which is comparable with Cl B 1.43 ml/min.kg in the horse, 1.52 ml/min.kg in sheep (BAGGOT, 1977); 1.48 ml/min.kg in horse (BAGGOT et al., 1981), and 1.5 ml/min.kg in the dog (BAGGOT, 1977), and 1.67 ml/min.kg in buffalo heifers (MUHAMMAD et al., 1999). Table 1. Pharmacokinetic parameters of kanamycin following a single intravenous injection of 5 mg/kg b. w. in 8 female mules Kinetic parameters Units Average ± SD C P µg/ml 22.1 ± 7.95 A µg/ml 14.2 ± 6.65 B µg/ml 7.91 ± 2.07 α h -1 9.64 ± 5.98 β h -1 0.16 ± 0.02 t 1/2α h 0.18 ± 0.26 t 1/2ß h 4.39 ± 0.68 Ke1 h -1 0.76 ± 0.87 K 12 h -1 5.83 ± 4.15 K 21 h -1 3.49 ± 1.92 Vc L/kg 0.25 ± 0.09 Vd (area) L/kg 0.64 ± 0.17 Vd ss L/kg 0.60 ± 0.13 Cl B m1/min.kg 1.66 ± 0.22 Based on the pharmacokinetics of kanamycin, a dosage regimen was calculated considering 2 mg/ml as the optimum minimum inhibitory concentration (MIC) for most equine pathogens (BAGGOT et al., 1985). Priming and maintenance doses were calculated as 8.73 and 7.45 mg/kg b.m., respectively, with a dosing interval of 12 hours to maintain the target 224 Vet. arhiv 73 (4), 221-226, 2003

trough MIC of 2 mg/ml. These doses are similar to 5 to 12 mg/kg/12 hours in cattle, sheep, dog and pigs (BOOTH and McDONALD, 1988) and 10.3 mg/ kg/12 hours and 8.4 mg/kg/12 hours in cows for priming and maintenance doses, respectively, (GHAFFAR et al., 1996), but higher than the manufacturer s recommendation of 5 mg/kg/24 hours. Compared with the manufacturer s recommended dosage regimen of 5 mg/kg/d, the clinical appraisal of dose 7.5 to 10 mg/kg b.i.d. in the Faculty s Veterinary Hospital revealed improved therapeutic response in equines, with no indication of toxicity in the animals. References ARRET, B. D., D. JOHNSON, K. AMIE (1971): Outline of details for microbiological assay of antibiotic. J. Pharmaceutical Sci. 60, 373-378. BAGGOT, J. D. (1977): Principles of Drug Disposition in Domestic Animals: The Basic of Veterinary Clinical Pharmacology, pp. 144-218. W. B. Saunders Co., Philadelphia. BAGGOT, J. D. (1978): Pharmacokinetics of kanamycine in dogs. J. Vet. Pharmacol. Therapeutics 1, 305-309. BAGGOT, J. D., N. D. LOVE, J. R. ROSE, R. RAUS (1981): The pharmacokinetics of some aminoglycosides antibiotics in the horses. J. Vet. Pharmacol. Therapeutics. 4, 277-284. BAGGOT, J. D., N. D. LOVE, J. R. ROSE, R. RAUS (1985): Selection of an aminoglycosides antibiotic for administration to horses. Equine Vet. J. 17, 30-34. BOOTH, N. H., L. E. MCDONALD (1988): The Veterinary Pharmacology and Therapeutics, 6 th ed. Iowa State Univ. Press/Ames. pp. 829-830. FUHUA, Z., X. ZHEN, Z. XINRU (1989): Pharmacokinetics studies of aminoglycosides antibiotics in buffaloes. In: Pharmacokinetics Studies of Antibiotics in Animals (K. F. Fung Ed.), Academic Press, China, pp. 26-29. GHAFFAR, T., T. IQBAL, M. NAWAZ (1996): Disposition kinetics and dosage of kanamycine in cows. Pakistan Vet. J. 16, 122-124. LASHEV, L. D., D. A. PASHOV, T. N. MARINKOV (1992): Interspecies differences in the pharmacokinetic of kanamycine and apraamycin. Vet. Res. Comm. 18, 293-300. MUHAMMAD, F., M. NAWAZ, T. KHALIQ, I. JAVED (1999): Disposition kinetics and dosage of kanamycine in buffalo heifers. Pakistan Vet. J. 19, 197-199. NAWAZ, M. (1994): Geonetical factors affecting biodisposition of drugs. Canad. J. Physiol. Pharmacol. Vol. 72, Suppl. 1, Abst. XII.2, p. 57. Intl. Cong. Pharmacol. 24-29 July, 1994, Montreal, Canada. NAWAZ, M., B. H. SHAH (1985): Geonetical considerations in the quality assurance of pharmaceuticals. Proc. Int. Seminar on Policies, Management and Quality Assurance Vet. arhiv 73 (4), 221-226, 2003 225

of Pharmaceuticals 21-28 th April, WHO and Ministry of Health Govt. of Pakistan, pp. 1-9. NAWAZ, M., T. IQBAL, R. NAWAZ (1988): Geonetical consideration in disposition kinetic evaluation of chemotherapeutic agents. Veterinary Pharmacology Toxicology and Therapy in Food Producing Animals. Vol. 2, p 260. Cong. Europ. Assoc. Vet. Pharmacol. Tharap. 28 August to 2 nd September, Budapest. Received: 15 August 2001 Accepted: 10 July 2003 MUHAMMAD, F., F. HUSSAIN, M. NAWAZ, I. JAVED: Kinetika raspodjele kanamicina u mula. Vet. arhiv 73, 221-226, 2003. SAŽETAK Istražena je farmakokinetika raspodjele kanamicina u zdravih, odraslih mula nakon jednokratne intravenske primjene u dozi 5 mg/kg tjelesne mase (t.m.) u zdravih odraslih mula. Uzorci krvi uzeti u razlièitim vremenskim razmacima bili su pretraženi na kolièinu kanamicina mikrobiološkim testom. Koncentracija lijeka u plazmi u odnosu na vrijeme najviše je odgovarala bieksponencijalnoj krivulji. Za izraèunavanje farmakokinetièkih pokazatelja rabljen je dvoprostorni otvoreni model. Rezultati su pokazali da je poluvrijeme raspodjele lijeka (t 1/2α ) iznosilo 0.18 ± 0.26, a poluvrijeme eliminacije (t 1/2β ) 4.39 ± 0.68 sati. Prividni volumen raspodjele lijeka (V d ) bio je 0.64 ± 0.17 l/kg, a ukupni klirens (Cl B ) 1.66 ± 0.22 ml/min/kg. Dozom 5 mg/kg t.m. jedanput na dan nije postignuta željena minimalna inhibicijska koncentracija (MIC) na kraju doznog razmaka. Izraèunato je da je optimalna udarna doza kanamicina za mule iznosila 8.73, a doza održavanja 7.45 mg/kg t.m. Pritom se lijek mora primjenjivati svakih 12 sati da bi se postigla koncentracija u krvi 2 mg/ml. Kljuène rijeèi: kanamicin, kinetika raspodjele, mula 226 Vet. arhiv 73 (4), 221-226, 2003